Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S066 - What's New in Dermatology

Tuesday, March 5; 10:30 AM - 12:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Treat psoriasis more effectively
  • Use new technologies to assess melanoma prognosis
  • Prescribe new therapies

Description

This session will review new technologies to assess prognosis in malignant melanoma; review the clinical presentation and tests to identify various infectious diseases; will review techniques in dermatologic surgery and cosmetic dermatology; will present new developments in pediatric dermatology; and will highlight new psoriasis therapies and new topical therapies as well as new vaccines and treatments for our patients.

Disclosures

  • Butterwick, Kimberly J., MD: Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(H); Colorescience – A(H); Evolus, Inc. – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Histogen Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – A(H); Revance Therapeutics, Inc. – A(H); Sinclair Pharma, LLC – Speaker/Faculty Education(H);
  • Eichenfield, Lawrence F., MD: Abbvie – I(Grants/Research Funding); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana BioSciences – Data Safety Monitoring Board(H); Cutanea Life Sciences – C(H); Dermavant Sciences, Inc. – C(H); Dermira – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Forte – A(H); Galderma Laboratories, L.P. – C(H), I(Fees); Glenmark Pharmaceuticals, Inc. – Data Safety Monitoring Board(H); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Matrisys – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H); Pfizer – I(Grants/Research Funding); Pfizer Inc. – C(H); Sanofi/Regeneron – C(H), I(Fees); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); verrica – A(SO); Verrica – C(H); verrica – I(Grants/Research Funding); Wiley-Blackwell – O(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Menter, Alan, MD: AbbVie – A(H), C(H), I(Grants/Research Funding), SP(H); Afecta Pharmaceuticals – A(NC); Amgen – A(Grants/Research Funding), C(H), I(Grants/Research Funding), SP(H); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding), I(H); Janssen Biotech – SP(H); Janssen Pharmaceuticals, Inc – A(H), C(H), I(Grants/Research Funding); LEO Pharma, US – A(H), C(H), SP(H); Medscape – A(H); Merck & Co., Inc – I(Grants/Research Funding); Novartis – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Sienna Biopharmaceuticals – C(H); UCB – C(H), I(H), SP(H); Valeant Pharmaceuticals North America LLC – C(Fees); Wyeth Labs – C(H), SP(H);
  • Rigel, Darrell S., MD: Aclaris Therapeutics, Inc. – C(H); Beiersdorf, Inc. – A(H); Castle Biosciences – A(H), I(Grants/Research Funding); Derm Tech International – A(H), C(H); Ferndale Laboratories, Inc. – C(H); Foamix – SH(SO); LEO Pharma, US – A(H); Myriad Genetics Inc – A(H); Novartis – A(H); Ortho Dermatologics – A(H); Pierre Fabre Dermo-Cosmétique US – A(H); SciBASE – C(H);
  • Stein Gold, Linda F., MD: AbbVie – A(H); Actavis – SP(H); Allergan, Inc. – I(Grants/Research Funding); Aqua – A(H); Botanix Pharmaceuticals – C(H); Dermavant Sciences – A(H); Dermira – SP(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – A(H); Leo Pharma Inc. – I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – A(H); Merz Pharmaceuticals, LLC – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Promius Pharmaceuticals – A(H); Roche Laboratories – Independent Contractor(Fees), O(H); Sol-Gel Technologies – C(Grants/Research Funding); Taro Pharm – A(H), C(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Schedule
Tuesday, March 5
10:30 AM
Dr. Lebwohl / Introduction
10:32 AM
Dr. Rigel / What's new in cutaneous oncology
10:48 AM
Dr. Tomecki / What's new in infectious disease
11:04 AM
Dr. Butterwick / What's new in dermatologic surgery & cosmetic dermatology
11:20 AM
Dr. Eichenfield / What's new in pediatric dermatology
11:36 AM
Dr. Menter / What's new in psoriasis
11:52 AM
Dr. Stein Gold / What's new in topical therapy
12:08 PM
Dr. Lebwohl / What's new in systemic dermatologic therapy
Event Details
  • Date
    Tuesday, March 5
  • Time
    10:30 AM - 12:30 PM
  • Location
    Ballroom C
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
Speakers
  • Alan Menter, MD, FAAD
  • Darrell S. Rigel, MD, FAAD
  • Kenneth J. Tomecki, MD, FAAD
  • Kimberly J. Butterwick, MD, FAAD
  • Lawrence F. Eichenfield, MD, FAAD
  • Linda F. Stein Gold, MD, FAAD